ASCO: Neoadjuvant Immunotherapy Wows in Early Stage Melanoma
Neoadjuvant immunotherapy for early stage melanoma is showing promise, new research shows. Fully 59% of patients responded so well to neoadjuvant immunotherapy that adjuvant treatment is no longer needed, according to the results of the NADINA study, which were presented the 2024 American Society of Clinical Oncology (ASCO) meeting in Chicago and published in New […]